Neuroprotection in Parkinson Disease
- 21 January 2004
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA
- Vol. 291 (3) , 358-364
Abstract
Review from JAMA — Neuroprotection in Parkinson Disease — Mysteries, Myths, and Misconceptions — Parkinson disease is an age-related neurodegenerative disease that affects approximately 1 million persons in the United States. Current therapies provide effective control of symptoms, particularly in the early stages of the disease, but most patients develop motor complications with long-term treatment, and features develop such as postural instability, falling, and dementia that are not adequately controlled with existing medications. Accordingly, neuroprotective therapy that might slow, stop, or reverse disease progression is urgently needed. While many agents appear to be promising based on laboratory studies, selecting clinical end points for clinical trials that are not confounded by symptomatic effects of the study intervention has been difficult. More recently, neuroimaging end points have been used as biomarkers of disease progression, but again there are concerns that they may be influenced by regulatory effects of the drugs used. We review clinical trials aimed at detecting neuroprotection in Parkinson disease and address the controversies surrounding the interpretation of these studies.Keywords
This publication has 24 references indexed in Scilit:
- Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell linesBiochemical Journal, 2003
- Agonists vs levodopa in PDNeurology, 2003
- Initial agonist treatment of Parkinson diseaseNeurology, 2003
- Are Dopamine Receptor Agonists Neuroprotective in Parkinson??s Disease?Drugs & Aging, 2001
- Parkinson Disease in TwinsJAMA, 1999
- Protein Kinase A Activity May Kinetically Upregulate the Striatal Transporter for DopamineJournal of Neuroscience, 1998
- A radical hypothesis for neurodegenerationTrends in Neurosciences, 1993
- Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levelsAnnals of Neurology, 1993
- D2Receptors May Modulate the Function of the Striatal Transporter for Dopamine: Kinetic Evidence from Studies In Vitro and In VivoJournal of Neurochemistry, 1993
- Unaltered [3H]GBR-12935 binding after chronic treatment with dopamine active drugsPsychopharmacology, 1990